Novartis expects profit and sales to grow further this year after beating analysts’ expectations, boosted by revenue from its ...

Bernstein analyst Florent Cespedes maintained a Buy rating on Novartis AG (NOVN – Research Report) today and set a price target of ...

European shares were at a record high on Friday, led by technology and healthcare stocks, even as caution prevailed ahead of ...

Jefferies analyst Peter Welford maintained a Hold rating on Novartis AG (NOVN – Research Report) today and set a price target of ...

The president confirmed his long-threatened tariffs will come into effect on Saturday, and said they “may or may not rise ...

Novartis on Friday posted quarterly adjusted net income well above analyst estimates on forecast-beating sales of established ...

After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. | The rising class of bisepcifics ...

After the DeepSeek-induced ruction on Tuesday, Big Tech earnings reminded investors that it might be better to focus on ...

Novartis said profit will rise this year as new medicines help offset competition from copycats of its best-selling drug.

Swiss pharmaceutical giant Novartis on Friday reported fourth-quarter results after repeatedly raising its full-year guidance ...

Ad hoc announcement pursuant to Art. 53 LR Full year Net sales grew +12% (cc1, +11% USD) with core operating income1 up +22% (cc, +19% USD) Sales growth driven by continued strong performance ...